CELLCEPT (mycophenolate mofetil) by Roche is (mmf) is absorbed following oral administration and hydrolyzed to mycophenolic acid (mpa), the active metabolite. First approved in 1997.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
CellCept (mycophenolate mofetil) is an oral immunosuppressant approved in 1997 that works by selectively inhibiting inosine monophosphate dehydrogenase (IMPDH) to block guanosine nucleotide synthesis in lymphocytes. It is used primarily for prevention of organ rejection in transplant recipients and treatment of autoimmune conditions. MPA shifts T and B lymphocytes from a proliferative to catabolic state, reducing antibody production and inflammatory cytokine release.
Product is approaching loss of exclusivity with modest Part D volume, signaling transition from growth to maintenance-mode commercial operations.
(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CELLCEPT at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCellCept offers limited career growth due to its LOE-approaching status and small commercial footprint (0 linked job postings). Roles on this franchise are primarily defensive and maintenance-focused, suited for professionals managing mature products or preparing for generic transition.